ATE151078T1 - Verfahren und zwischenprodukte synthetischer antikörperderivate - Google Patents

Verfahren und zwischenprodukte synthetischer antikörperderivate

Info

Publication number
ATE151078T1
ATE151078T1 AT91908713T AT91908713T ATE151078T1 AT E151078 T1 ATE151078 T1 AT E151078T1 AT 91908713 T AT91908713 T AT 91908713T AT 91908713 T AT91908713 T AT 91908713T AT E151078 T1 ATE151078 T1 AT E151078T1
Authority
AT
Austria
Prior art keywords
intermediates
intermediate products
synthetic antibodies
chimeric antibodies
antibody derivatives
Prior art date
Application number
AT91908713T
Other languages
English (en)
Inventor
George Stevenson
Original Assignee
3I Res Expl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3I Res Expl Ltd filed Critical 3I Res Expl Ltd
Application granted granted Critical
Publication of ATE151078T1 publication Critical patent/ATE151078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT91908713T 1990-04-23 1991-04-22 Verfahren und zwischenprodukte synthetischer antikörperderivate ATE151078T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009106A GB9009106D0 (en) 1990-04-23 1990-04-23 Processes and intermediates for synthetic antibody derivatives

Publications (1)

Publication Number Publication Date
ATE151078T1 true ATE151078T1 (de) 1997-04-15

Family

ID=10674863

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908713T ATE151078T1 (de) 1990-04-23 1991-04-22 Verfahren und zwischenprodukte synthetischer antikörperderivate

Country Status (7)

Country Link
US (1) US6136313A (de)
EP (1) EP0528856B1 (de)
JP (1) JPH05507268A (de)
AT (1) ATE151078T1 (de)
DE (1) DE69125485T2 (de)
GB (1) GB9009106D0 (de)
WO (1) WO1991016354A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP4870569B2 (ja) 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
ZA200604864B (en) * 2003-12-19 2007-10-31 Genentech Inc Monovalent antibody fragments useful as therapeutics
US20070014789A1 (en) * 2005-07-15 2007-01-18 Bayer Healthcare Llc Humanized antibody conjugates and related methods, assays, reagents, and kits
RS54088B1 (en) 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
WO2007086994A1 (en) * 2005-11-15 2007-08-02 Balyasnikova Irina V Single chain fragment of monoclonal antibody 9b9 and uses thereof
US20080108147A1 (en) * 2006-11-03 2008-05-08 Tie Wei Reduction of non-specific binding in immunoassays
US20090252729A1 (en) * 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
NZ588671A (en) 2008-04-11 2012-11-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2968498A4 (de) 2013-03-15 2016-09-07 Biogen Ma Inc Faktor-ix-polypeptidformulierungen
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux

Also Published As

Publication number Publication date
US6136313A (en) 2000-10-24
DE69125485D1 (de) 1997-05-07
JPH05507268A (ja) 1993-10-21
GB9009106D0 (en) 1990-06-20
EP0528856B1 (de) 1997-04-02
WO1991016354A1 (en) 1991-10-31
EP0528856A1 (de) 1993-03-03
DE69125485T2 (de) 1997-07-24

Similar Documents

Publication Publication Date Title
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
DE69119278D1 (de) Monoklonaler Antikörper, der mit einer neuen HLA-Determinante auf MHC-Klasse-I-Moleküle reagiert, und Verfahren zur Aktivierung von Lymphozyten
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
ATE208820T1 (de) Humanisierte antikoerper
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
DE69128543T2 (de) Monoklonale antikörper der maus
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
DE3686811D1 (de) Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.
SE8404334D0 (sv) 16-fluoro-16,17-didehydro-prostanoids and process for their preparation
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
ATE155481T1 (de) Verfahren zur reinigung von streptolysin 0, intaktes streptolysin 0 erhältlich nach diesem verfahren und seine verwendung
DE59104391D1 (de) Verfahren zur Behandlung von Faserverbundwerkstoffen.
HU9300349D0 (en) Method for producing dibenzo- or benzo-pyrido-cyclohepta-piperidine derivatives or piperidylidene or piperazine derivatives thereof as well as pharmaceutical preparatives contqining them
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
DK0858465T3 (da) Protein med antitumorvirkning.
DK0421382T3 (da) Monoklonalt antistof mod exotoxin A fra Pseudomonas aeruginosa
OA07542A (fr) Nouveaux dérivés stéroïdes substitués en 11b, procédé et intermédiaires de préparation, leur application comme médicament et les compositions les renfermant.